INTRODUCTION
Follicular lymphoma (FL) constitutes approximately 20% of all newly diagnosed lymphoma cases, 1 making it the second most common subtype of nonHodgkin's lymphoma worldwide and the most common subtype seen in North America. 2 It is characterized by an indolent clinical course, typical morphology, and the presence of a chromosomal translocation, t(14;18)(q32;q21) or variant in 85% of patients. This chromosomal aberration results in the juxtaposition of the immunoglobulin heavy chain gene (IGH) on chromosome 14 with the BCL2 oncogene on chromosome 18 leading to constitutive, and therefore inappropriate, expression of the BCL2 protein. Overexpression of BCL2 confers relative resistance to apoptosis, thus giving the cells a survival advantage that may facilitate the acquisition and retention of secondary genetic abnormalities.
FL is a heterogeneous entity with some patients developing progressive or transformed disease early and 15% dying within 2 years from diagnosis, while others remain alive for decades without need for treatment. This variability in outcome underscores the necessity to gain further insight into the biology and clinical behavior of the disease to enable individualized therapy.
TREATMENT AND CLINICAL COURSE
The median age at diagnosis of FL is 59 years with a male to female ratio of 1:1.7.
3 FL is typically diagnosed in the advanced stages, with only 26% to 33% of patients presenting with stage I to II disease.
3,4
With conventional chemotherapy, even if combined with radiotherapy, advanced-stage FL is incurable. It is characterized by an indolent course with patients developing slowly progressive lymphadenopathy over many years, with or without constitutional B symptoms (eg, fever, weight loss Ͼ 10%, drenching night sweats). Temporary, spontaneous regressions occur in 20% of patients managed without initial therapy. 5 Historically, median survival has ranged from 6 to 10 years. [4] [5] [6] [7] Transformation to an aggressive lymphoma occurs at a rate of 3% per year and is associated with substantial morbidity and mortality. 8, 9 Transformation is defined as the development of a more aggressive histology lymphoma, most commonly diffuse large B-cell lymphoma (DLBCL), that is thought to be clonally related to the original FL.
Limited-stage FL treated with external-beam radiotherapy results in prolonged remission in 30% to 50% of patients and an apparent plateau on the disease-free survival curve after 15 to 20 years. 10, 11 Two randomized studies showed that deferred initial treatment in asymptomatic advanced-stage patients does not compromise long-term outcome or risk of transformation. 7, 12 FL is highly sensitive to antineoplastic agents early, but grows increasingly resistant with successive lines of therapy.
rituximab to chemotherapy has resulted in a higher rate of complete remission (CR) and prolonged remission duration without increasing clinically relevant toxicity. 15 Several studies have confirmed an improvement in overall survival (OS) with immunochemotherapy as the initial treatment for FL. [15] [16] [17] Furthermore, rituximab as maintenance therapy after induction therapy for relapse improves progression-free survival (PFS) and OS. 18 However, an improved survival for patients diagnosed with FL has been noted over the past 25 years, 19 an effect at least in part predating the introduction of rituximab, likely explained by improved diagnosis and supportive care.
CLINICAL PARAMETERS

Multiparameter Indices
The International Prognostic Index (IPI), originally developed for aggressive lymphoma, identifies four risk groups based on age, tumor stage, serum lactate dehydrogenase (LDH) level, performance status, and number of extranodal sites of disease. 20 The IPI also reliably identifies risk groups among FL [21] [22] [23] ; however, it only classifies a small proportion of patients into the highest-risk category.
Three prognostic indices have been developed specifically for FL. The Italian Lymphoma Intergroup (ILI) index identifies three risk groups with 10-year survival rates of 65%, 54%, and 11% based on six clinical parameters (advanced age, male sex, number of extranodal sites of disease, B symptoms, serum LDH level, and erythrocyte sedimentation rate). 24 In 2004, the Follicular Lymphoma International Prognostic Index (FLIPI) was published resulting from a multicenter effort.
25 It includes five parameters: age (Ͼ 60 v Յ 60 years), stage (III-IV v I-II), anemia (hemoglobin Ͻ 120 v Ն 120 g/L), number of involved nodal areas (Ͼ 4 v Յ 4), and serum LDH (elevated v normal), and classifies patients into three groups with 10-year OS rates of 71%, 51%, and 36%, respectively. The FLIPI is predictive in patients treated with immunochemotherapy, 26 can be applied in first relapse, 27 and predicts transformation. 28 The IPI, FLIPI, and ILI indices have been directly compared, all identifying somewhat different risk groups. 29 Recently, the FLIPI-2 index was published, incorporating beta-2 microglobulin, lymph node size larger than 6 cm, bone marrow involvement, anemia, and age older than 60 years (Table 1) . 25, 30, 36 All of these clinical indices are robust, easy to use in clinical practice, and of value for stratification in clinical trials; however, marked variations in outcome remain within each risk group.
Biomarkers in Blood and Bone Marrow
There are conflicting reports regarding the prognostic impact of bone marrow (BM) involvement by FL. BM involvement was associated with decreased survival in several investigations including those of the ILI and the FLIPI. 24, 25, 32, 33 In contrast, others have not found BM involvement in itself to affect survival, 34 but rather the histologic pattern 35 or degree of marrow involvement. 36 Importantly, BM status at the time of diagnosis has been included in the FLIPI-2. 30 The characteristic t(14;18)(q32;q21) generates a BCL2-IGH fusion gene, which can be used as a marker of disease detectable by polymerase chain reaction (PCR) . 37 This technique is highly sensitive and can routinely detect one translocation-positive cell in 10 6 cells in peripheral blood (PB) or BM. PCR has been used for detecting minimal residual disease (MRD) after therapy. 38 Three different break points within the BCL2 gene have been identified in FL. [39] [40] [41] However, the value of molecular monitoring in FL has not yet been established. Despite attaining a CR after chemotherapy, the BM remained positive by PCR in all or most patients without clear prognostic impact in some reports, 42-44 whereas others have found molecular CRs to be common. 45 Rambaldi et al 46 reported that the degree of BM involvement by lymphoma by quantitative real-time PCR before rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) therapy was predictive of outcome and that patients attaining molecular CR experienced a prolonged freedom from relapse.
Currently, the implication of the presence of t(14;18)-positive cells detected by PCR remains unknown. Not all PCR-positive patients relapse, and some convert to PCR negativity without therapy. 47 Furthermore, t(14;18)-positive cells have been found in patients in long-term remission after therapy for FL 48, 49 and BCL2 translocations have been detected by PCR in PB from healthy individuals and from autopsies from patients without lymphoma.
50,51
Other Biomarkers in Blood
Biomarkers readily measurable from the PB that have been correlated with outcome in FL are summarized in Table 2. 52-67 Beta-2 microglobulin has reached wide acceptance as a prognostic marker and is included in FLIPI-2, 31 but is not universally available in retrospective cohorts.
24,25 LDH is a robust prognostic factor in several types of lymphoma; however, in FL it is elevated in only 20% of patients.
24,25 Serum angiogenic factors have been analyzed in heterogeneous groups of patients with lymphoma with partly conflicting results. 59, 60, 61, 63, 68 Interestingly, polymorphisms leading to high expression of tumor necrosis factor may influence outcome in non-Hodgkin's lymphoma, pointing to the importance of host factors.
62,64-66
PATHOLOGIC PARAMETERS
FL is a neoplasm of germinal center B cells that mimic the architecture of normal secondary lymphoid follicles. Benign and malignant follicles contain a heterogeneous mixture of non-neoplastic cells including T cells, benign B cells, follicular dendritic cells (FDC), and macrophages. The majority of patients with FL manifest two major types of neoplastic B cells: small centrocytes and larger centroblasts. Histologic grading of FL is based on the relative proportions of these two cell types.
Histologic Grade
The current WHO classification recognizes three histologic grades (grades 1 to 3) of FL. 69 Grading of FL is poorly reproducible 
79
BCL2 and BCL2 family proteins. The family of BCL2-related proteins plays a central role in the surveillance of mitochondrial integrity by balancing between pro-and antiapoptotic members. Only a few of these proteins have been studied in relationship to prognosis in FL and no consistent correlation has been found. 80 As a possible exception, a high number of MCL1-positive centroblasts has been correlated with poor OS. 81 Similarly, expression of the long RNA isoform of BCLX L has been correlated with prognosis in FL, 82 however, expression of the protein did not.
83
Using reverse-phase protein microarrays, when microdissected follicles from reactive lymph nodes were compared with follicles with FL, most proapoptotic and antiapoptotic proteins except for BCL2 were present at comparable levels in BCL2-positive and BCL2-negative tumors with activation of the AKT/BAD signaling pathway. 84 Gulmann et al 85 also used a proteomic approach to analyze apoptotic pathways in FL. They found phosphorylation of AKT to be frequent in FL suggesting that it may act as an antiapoptotic agent along with BCL2. High ratios of BCL2/BAK and BCL2/BAX were associated with early death from disease. The expression patterns of other proapoptotic members of the BCL2 family have largely unknown clinical impact. 86 Future studies on the role of BCL2 family proteins in FL are needed as they may identify patients who will benefit from novel BH3 mimetics, small molecules that specifically target BCL2 proteins.
87,88
Germinal center-related markers. BCL6 encodes a zinc finger transcription factor involved in germinal center formation. CD10 is a membrane metalloendopeptidase expressed in the germinal center. In FL, these two markers of germinal center origin are expressed in more than 95% and 75% of cases, respectively. 89 Although their prognostic significance is established in DLBCL, 90 their relevance in FL is less clear. Using immunohistochemical scoring systems to combine the percentage of positive malignant cells and their intensity of expression, the expression level of BCL6 has been correlated with favorable prognosis in FL.
91 PU.1 is an ETS-domain transcription factor essential for the development of myeloid and B lymphoid cells. Constitutive PU.1 expression inhibits the earliest B-cell development, and low levels of PU.1 expression in hematopoietic progenitor cells are instrumental in promoting B-cell fate determination. 92 Torlakovic et al 93 studied the clinical impact of proteins associated with the germinal center in FL and found PU.1 protein expression, but not CD10 or BCL6, to be a favorable marker of OS independent of the FLIPI.
Cell cycle regulators. TP53 mutations have been reported in FL at diagnosis and are associated with an inferior survival. 94 The presence of mutations leading to overexpression of the TP53 protein has been associated with transformation.
95,96 Expression of TP53 protein is only moderately correlated with the presence of mutations (64%) and similarly with the expression of key regulators of TP53, such as CDKN1A or MDM2. 97 The latter have also been shown to correlate with transformation.
97,98 A gene expression profiling study of 57 patients with FL established a set of 14 genes that were highly expressed in patients with a favorable response to CHOP; however, only expression of CYCLIN B1 mRNA and protein level had prognostic impact independent of the FLIPI.
99
Others. SOCS3 is a cytokine suppressor that inhibits cytokine signaling by Janus kinase (ie, the JAK-STAT pathway). Overexpression of SOCS3 has been reported to be an independent unfavorable prognostic factor in FL. 100 Overexpression of Ying-Yang 1, a zincfinger protein regulating IL4 gene expression, has also been linked with shorter survival in FL.
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Cytogenetics and Molecular Genetics
Classical karyotyping. Cytogenetic analysis of FL reveals a wide range of recurrent, nonrandom chromosomal alterations. FL is characterized by the overexpression of the antiapoptotic protein BCL2 as a result of the t(14;18)(q32;q21) or its rare variants t(2;18) and t(18;22). t(14;18) is present in approximately 85% of grade 1 and 2 FL and although it is considered insufficient on its own to cause FL, it provides these B cells with a survival advantage leaving them prone to accumulate additional genomic abnormalities. 102 However, in a study of FL cases lacking the t(14;18), Horsman et al 103 found distinct patterns of recurrent chromosomal alterations. In another report, FLs lacking the t(14;18) were less likely to express CD10 or BCL2, were more likely to arise at extranodal sites and had a better OS. Recently, Katzenberger et al 104 described t(14;18)-negative FL characterized by a predominantly diffuse growth pattern, presenting clinically with large but localized inguinal tumors. The majority of FL patients without a t(14;18) have a deletion in 1p36.
The malignant cells in FL have an average of four to six different cytogenetic changes in addition to the BCL2 translocation.
105,106 Only 5% of FL have t(14;18) as the sole detectable abnormality. The most common abnormalities are break points in chromosome 1, deletions in the long arm of chromosome 6 (6qϪ), trisomy 7 (ϩ7), trisomy 12 (ϩ12), presence of a derivative of chromosome 18 (der(18), and duplication of X (ϩX). 106 Early studies suggested that the number of abnormalities and presence of certain alterations (6qϪ, ϩ7, ϩX, ϩ21) were associated with an inferior survival. 107 However, as karyotypic complexity increases after therapy, 108 reviewed the karyotypes of 336 cases of FL and, using principle components analysis, postulated distinct pathways of clonal evolution of chromosomal changes arising in a temporal order with early changes being 1qϩ, ϩ7, ϩ8,ϩ12, and ϩder(18) and later 2pϪ, 10pϪ, Ϫ15, 17pϪ, and 17qϪ. Based on the clinical data on 165 patients, ϩ12 and 17pϪ were correlated with an adverse outcome. In contrast, we recently reviewed 210 karyotypes from FL biopsies taken at diagnosis and found no association between the number or type of cytogenetic abnormalities with clinical outcome.
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Comparative genomic hybridization. Comparative genomic hybridization (CGH) can be performed by hybridizing tumor DNA against normal chromosomes (chromosomal CGH) or by using microarray platforms with spotted DNA probes (array CGH).
112 Viardot and colleagues 113 analyzed 124 samples of FL using chromosomal CGH and reported a number of recurrent alterations. In a subset analysis of 82 patients, loss of chromosomal material at 6q25-27 was a strong independent predictor of inferior survival. Cheung et al 114 identified two genomic regions, deletions in 1p36.22-p36.33 and 6q21-q24.3, to be highly associated with transformation and inferior OS in patients with FL using array CGH. Recently, Schwaenen et al 115 reported a large number of recurring genomic aberrations in FL as analyzed by array CGH, of which deletions in 9p21 (CDKN2A/B), 6q25, and 6q26 were associated with inferior survival.
Single nucleotide polymorphism arrays. Copy-neutral loss of heterozygosity, undetectable by previously available methods, can be identified using single nucleotide polymorphism (SNP) arrays. This phenomenon, termed acquired uniparental disomy (aUPD), results from mitotic recombination or nondisjunction and has been described in FL.
112,116 In a recent report, a number of recurring aUPDs were described in FL, of which aUPD on 1p36 correlated with shortened OS and aUPD on chromosome 16 was predictive of transformation.
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Host Constitutional Genetics
SNPs ] -8, IL2, IL12B, and IL1RN ). An outcome predictor was built using clinical and demographic factors combined with the four deleterious SNPs, which identified three risk groups with 5-year OS estimates of 96%, 72%, and 58%, respectively. These patients were treated in an era before the use of rituximab. Although these four genes strongly predict outcome in patients with FL, none of them has been shown to be associated with the risk of developing FL. 125, 126 Together with the gene expression profiling (GEP) data below, 127 these results suggest that the composition and functional status of the immune cells in the tumor microenvironment of FL may largely be driven by the genetics of the host.
Non-Neoplastic Cells of the Microenvironment
Lymph nodes involved with FL contain an admixture of nonneoplastic T cells, FDCs, macrophages, and other cells. A renewed interest in the microenvironment in FL followed the Leukemia Lymphoma Molecular Profiling Project (LLMPP) study in 2004 127 in which GEP of whole-section frozen lymph nodes from 191 cases of FL demonstrated that the tumor microenvironment was the most important predictor of patient outcome. Two signatures of gene expression were identified that best correlated with survival prediction. The immune-response 1 (IR-1) signature included genes encoding for T-cell markers and some genes that are highly expressed in monocytes/macrophages, and predicted a favorable outcome. The IR-2 signature included genes preferentially expressed in macrophages or dendritic cells, and predicted an unfavorable outcome. When patients were grouped into quartiles based on their survival-predictor scores, median survival rates ranged from 3.9 years to 13.6 years. These data highlighted the dominant prognostic role of the microenvironment in FL and suggested that the critical determinants of outcome might already be present at diagnosis.
After the LLMPP study, Glas et al 128 performed GEP in a series of patients with FL who were grouped according to outcome and transformation. They defined an 81-gene predictor that correlated with immediate clinical behavior but not with long-term survival or risk of transformation. Interestingly, the genetic profile of patients with early transformation exhibited an activated status of T cells, FDCs, and macrophages characterized by genes that were present in the favorable IR-1 signature of the LLMPP study. Differences in experimental design, patient selection, gene expression platforms, and data analysis may explain the different conclusions between these two studies.
Microvessel density. Despite evidence for a vital role of angiogenesis in supporting tumorigenesis, 129 some reports have suggested that increased vessel density correlates with better prognosis in FL. 130 Intriguing results by Streubel et al 131 demonstrated that endothelial cells of the microvasculature share the BCL2 rearrangement characteristic of FL, implying an intimate relationship between the two.
FDC meshwork "immaturity." In addition to presenting antigens, FDCs comprise the scaffolding of both benign and malignant follicles, their dendritic processes providing structural support for B cells and non-neoplastic cells. An immature FDC phenotype is typified by expression of low-affinity nerve growth factor and CNA.42, accompanied by absence of mature FDC markers such as CD21, CD35, CD23, and CXCL13. This phenotype typifies undifferentiated fibroblastic cells and has been reported to correlate with progression and/or transformation, 132 but not in all studies. 83 These changes correlate with loss of normal T-cell infiltration within follicles and might reflect a reduced cross-talk between these two cell types. Disruption of the tight FDC meshwork that characterizes FL has been associated with early transformation.
133
Macrophages. Tumor-associated macrophages have been described in a number of cancers, with increased numbers of benign macrophages typically associated with inferior survival. Farinha and colleagues 83 demonstrated that the small subset of FL cases with high macrophage content experienced markedly decreased OS and PFS independent of the IPI. These data appear consistent with the LLMPP GEP study, with high macrophage content being a surrogate for the IR-2 signature.
127 Alvaro et al 134 reported opposite results finding that increased macrophages were associated with indolent clinical behavior. In a related study, these same authors found that 30% of macrophages express STAT1 protein and that presence of this subset of cells was associated with inferior survival. 135 In two recent trials, a high macrophage content was associated with poor survival after chemotherapy, but not if combined with rituximab.
136,137
Macrophage plasticity has been well described, as these cells can be broadly separated into helper (M1) and healer (M2 or activated) cell types. 138 In most tumors, tumor-associated macrophages are polarized to a M2 phenotype and appear to create a trophic environment that favors the tumor cells. 139 A pan-macrophage marker (CD68) cannot capture these distinctions and may explain the discordant results.
T-cell subsets. 145 immunophenotype that serve a critical role in regulating CD4 and CD8 effector functions by suppressing proliferation and cytokine production of these cells. 146 In epithelial malignancies, Tregs have been implicated in creating an immunosuppressed microenvironment that allows the tumor cells to escape the host immune response.
147 Some investigators have reported that an increased number of Tregs was associated with favorable clinical behavior in FL, 134, 141 while others claim that the T-cell distribution may be more relevant. 143, 148 Recently, a low number of tumor-infiltrating programmed cell death 1-positive was associated with transformation and with inferior survival. 149 Still, the precise role of T-cell subsets in FL biology remains unclear. The clinical impact of these cells in the microenvironment may be largely influenced by the characteristics of the patient and the treatments received. 145 Specific therapies may have different effects on neoplastic cells versus cells within the microenvironment. Moreover, the role of host genetics influencing the immune microenvironment has only recently been explored.
125
Transformation
Histologic transformation is often heralded by a sudden change in clinical behavior, such as a rise in serum LDH or development of unusual extranodal sites of disease. It is a dominant clinical event, associated with shortened survival and relative resistance to therapy. The reported frequency varies dramatically ranging from 5% to 60% of patients with FL. 5, 8, [150] [151] [152] [153] [154] [155] [156] Since risk of transformation is time dependent, approximately 3% per year, this variation probably reflects differing durations of follow-up. The length of time that patients are followed and the rigor with which biopsies are obtained at progression heavily affect the reported frequency. Biomarkers that predict for survival do not necessarily correlate with those that predict risk of transformation.
An association between increased FLIPI score and frequency of transformation has been noted. 9, 28 Morphologic features associated with transformation risk include the presence of diffuse areas and disruption of the FDC meshwork.
132,157 The presence of grade 3B FL and increased intrafollicular CD4-positive T cells have also been linked to early transformation. 133 Studies using paired samples (FL and subsequent DLBCL) have demonstrated that transformation is a molecularly heterogeneous event, including loss of TP53, loss of the CDKN2A tumor suppressor, or acquisition of MYC translocations, leading to upregulation of MYC or its target genes. 95, 96, 98, [158] [159] [160] [161] [162] [163] Other molecular alterations include mutations of the coding region of BCL2 and translocations involving BCL6. 164, 165 Cytogenetic studies of paired samples have revealed candidate chromosomal alterations, including ϩ7, ϩ12q13-14, and Ϫ6q16-21.
166-170 Lastly, a number of small studies using gene expression profiling of paired samples have been published. 160, [170] [171] [172] [173] These demonstrate the molecular heterogeneity underlying transformation, implicating upregulation of p38 MAP KINASE, upregulation of MYC and its target genes, and a generic increase in the mitotic machinery.
Recent data suggest that FL may comprise two major patient subgroups; those destined to develop transformation and those who will not.
9 Distinguishing between these two clinical risk groups might have major implications for therapy.
Translation Into the Clinic
A summary of factors associated with outcome in FL is shown in Figure 1 . As presented in Tables 2, 3, and 4, 174-188 consensus on which biomarkers to use in clinical practice and how these might impact treatment decisions is still lacking. Most prognostic markers were studied before the introduction of rituximab and require validation in the current era of chemoimmunotherapy. At this time, disease behavior and robust indices, such as the FLIPI and FLIPI-2, remain the basis for clinical decision making. The key elements in the interaction of host immunogenetics, tumor microenvironment, and therapy in FL are still not well understood (Fig  2) . The inclusion of correlative science into clinical trials should help to determine the precise role of biomarkers in predicting survival and transformation risk in FL. Prospective randomized clinical trials will be instrumental in defining future prognostic factors in FL, as uniform treatment groups can be compared (Fig  3) . If patients who respond poorly to standard therapy can be identified and the mechanism(s) underlying their inferior outcome determined, these patients could reasonably be considered candidates for novel therapies with the potential for improved outcome avoiding toxicity from ineffective therapy. 
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